Cytiva Delivers Chinese Biomanufacturing Facility to Lonza
The 17,000 m2 facility will serve as a process development and manufacturing site for Chinese companies developing medicines as well as multinationals with manufacturing requirements in China.
Cytiva announced on Jan. 14, 2021 that it has completed a KUBio installation for Lonza in the form of a high throughput modular biomanufacturing facility in Guangzhou Biopark, China.
The 17,000 m2 facility will serve as a process development and manufacturing site for Chinese companies developing medicines, as well as multinationals with manufacturing requirements in China, Cytiva said in a company press release. The site will feature 6500 m2 of lab space and one KUBio modular facility, which will accelerate antibody development services and manufacturing.
“The Cytiva team showed great agility and speed in delivering this important site,” said Stefan Stoffel, chief operating officer, Lonza, in the press release. “With the KUBio and FlexFactory single-use platform now ready for business, Lonza will be able to respond to the great demand for innovative therapies in the current environment, now and in the future.”
“In a rapidly-growing industry with increasing needs for mAbs [monoclonal antibodies] and other key biopharmaceuticals, this facility demonstrates the strength of combining modular manufacturing with single-use technologies,” added Olivier Loeillot, vice-president, Cytiva, in the press release. “Together, the KUBio and FlexFactory speed up delivery of innovative therapeutics to patients who need them.”
Source: Cytiva
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
